01—Abstract
Summary
Summary of the 10-Q filed May 9, 2025. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc. reported solid first-quarter 2025 results, with net revenues increasing by 8.4% to $13.3 billiona, driven by robust growth in its immunology franchise, particularly Skyrizi and Rinvoq, which saw significant year-over-year increases.
Despite the overall revenue growth, the company experienced a 50.6% decline in Humira revenue due to ongoing biosimilar competition, highlighting the strategic shift towards its newer growth drivers. Diluted earnings per share were $0.72b, a slight decrease from the prior year's $0.77, impacted by higher interest expenses and a significant increase in the change in fair value of contingent consideration liabilities, which rose to $1.5 billion from $660 million in the prior year. The company continued its strategic investment in pipeline expansion and business development, highlighted by the acquisition of Nimble Therapeutics for oral peptide therapeutics and the finalization of the Cerevel Therapeutics acquisition for neuroscience indications.
Cash flow from operations saw a notable decrease to $1.6 billionc from $4.0 billion in the prior year, primarily due to working capital timing and litigation-related payments, though the company maintains strong liquidity with significant credit facilities available. AbbVie also continued its commitment to returning capital to shareholders through consistent dividend payments and share repurchases.
02—Key points
Key Highlights
- Net revenues grew 8.4% to $13.3 billion, driven by strong performance in Skyrizi (+70.5%) and Rinvoq (+57.2%).
- Humira revenue declined significantly by 50.6% due to biosimilar competition, underscoring the company's transition to newer growth drivers.
- Diluted EPS was $0.72, down from $0.77 in the prior year, impacted by increased interest expense and higher changes in fair value of contingent consideration.
- Acquired Nimble Therapeutics for $288 million, focusing on oral peptide therapeutics for conditions like psoriasis.
- Completed final valuation of the Cerevel Therapeutics acquisition, strengthening its neuroscience portfolio.
- Cash flow from operations decreased to $1.6 billion from $4.0 billion, largely due to working capital timing and litigation payments.
- AbbVie declared a quarterly dividend of $1.64 per share and continued its share repurchase program.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2025, AbbVie Inc. kept $0.10.
- Revenue$13.34B100.0%
- Cost of revenue−$4.00B30.0%
- Gross profit$9.34B70.0%
- Operating costs−$5.61B42.0%
- Operating income$3.73B28.0%
- Interest, other & tax−$2.45B18.3%
- Net income$1.29B9.6%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed May 9, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $13.34B$12.31B | +8.4% |
| Cost of Revenue | $4.00B$4.09B | −2.2% |
| Gross Profit | $9.34B$8.22B | +13.7% |
| SG&A Expenses | $3.29B$3.31B | −0.7% |
| Operating Expenses | $9.61B$9.51B | +1.0% |
| Operating Income | $3.73B$2.80B | +33.4% |
| Interest Expense | $700.00M$660.00M | +6.1% |
| Net Income | $1.29B$1.37B | −6.1% |
| EPS (Basic) | $0.72$0.77 | −6.5% |
| EPS (Diluted) | $0.72$0.77 | −6.5% |
| Shares Outstanding (Basic) | 1.77B1.77B | −0.1% |
| Shares Outstanding (Diluted) | 1.77B1.77B | −0.1% |
05—Questions
Frequently Asked Questions
What are the main drivers of AbbVie's revenue growth in Q1 2025?
AbbVie's revenue growth in the first quarter of 2025 was primarily driven by strong performance in its immunology products, Skyrizi and Rinvoq, which saw substantial increases in net revenues. The company also experienced growth in certain neuroscience and oncology products.
What is the impact of Humira's declining sales on AbbVie's financial performance?
Humira's sales decreased by over 50% in Q1 2025 due to the ongoing impact of biosimilar competition. While this represents a significant headwind, AbbVie is strategically relying on its newer growth drivers like Skyrizi and Rinvoq to offset this decline and continue overall company growth.
How did acquisitions affect AbbVie's financial results in the quarter?
AbbVie completed the acquisition of Nimble Therapeutics and finalized the valuation for the Cerevel Therapeutics acquisition. These strategic moves are aimed at expanding its pipeline and therapeutic reach, particularly in neuroscience and novel drug modalities. While these acquisitions contribute to long-term strategy, they also involve integration costs and may impact reported earnings through changes in fair value of contingent consideration.
What is the outlook for AbbVie's cash flow from operations?
Cash flow from operations decreased significantly in the first quarter of 2025 compared to the prior year. This was attributed to the timing of working capital movements and payments related to litigation matters. AbbVie continues to generate substantial cash flow from its operations, and it maintains access to significant credit facilities to ensure liquidity.
06—Continue